Flossbach Von Storch SE Grows Holdings in Ralliant Corporation $RAL

Flossbach Von Storch SE lifted its stake in shares of Ralliant Corporation (NYSE:RAL) by 1.7% in the third quarter, Holdings Channel reports. The institutional investor owned 4,152,866 shares of the company’s stock after buying an additional 67,963 shares during the quarter. Flossbach Von Storch SE’s holdings in Ralliant were worth $181,605,000 as of its most recent SEC filing.

Other institutional investors have also recently added to or reduced their stakes in the company. Westfuller Advisors LLC acquired a new position in Ralliant during the 3rd quarter worth $26,000. Manchester Capital Management LLC bought a new position in shares of Ralliant during the second quarter worth about $29,000. Webster Bank N. A. acquired a new position in Ralliant in the third quarter worth about $31,000. Evermay Wealth Management LLC bought a new stake in Ralliant in the second quarter valued at about $32,000. Finally, Wilmington Savings Fund Society FSB bought a new stake in Ralliant in the third quarter valued at about $34,000.

Ralliant Price Performance

Shares of RAL opened at $52.95 on Thursday. Ralliant Corporation has a 12 month low of $40.70 and a 12 month high of $55.25. The company has a debt-to-equity ratio of 0.39, a current ratio of 1.49 and a quick ratio of 1.03. The stock has a fifty day moving average price of $51.19 and a 200 day moving average price of $46.60. The company has a market cap of $5.97 billion and a P/E ratio of 41.69.

Ralliant (NYSE:RAL) last announced its quarterly earnings results on Wednesday, November 5th. The company reported $0.60 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.58 by $0.02. The firm had revenue of $529.10 million for the quarter, compared to analyst estimates of $519.14 million. Ralliant has set its Q4 2025 guidance at 0.620-0.680 EPS.

Analyst Upgrades and Downgrades

RAL has been the subject of several research reports. Barclays lifted their target price on Ralliant from $59.00 to $60.00 and gave the stock an “overweight” rating in a research report on Wednesday, January 7th. Weiss Ratings restated a “hold (c)” rating on shares of Ralliant in a research note on Monday, December 29th. Oppenheimer boosted their target price on shares of Ralliant from $55.00 to $60.00 and gave the company an “outperform” rating in a research note on Monday, December 15th. Truist Financial began coverage on shares of Ralliant in a report on Friday, December 12th. They set a “buy” rating and a $62.00 target price on the stock. Finally, Royal Bank Of Canada lifted their price target on shares of Ralliant from $45.00 to $52.00 and gave the company a “sector perform” rating in a report on Friday, November 7th. Six research analysts have rated the stock with a Buy rating and four have given a Hold rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $58.00.

Ralliant Profile

Ralliant, Inc (NYSE: RAL) is a medical technology company focused on enabling point-of-care cell therapy solutions in the field of regenerative medicine. The company develops and markets systems that isolate, concentrate and store adipose-derived stromal vascular fraction (SVF) cells directly from a patient’s own fat tissue, facilitating same-day, autologous treatments without the need for extensive laboratory infrastructure.

The company’s core product portfolio includes proprietary device platforms and single-use processing kits engineered to streamline the workflow for clinicians.